What is HC Wainwright’s Estimate for WVE FY2026 Earnings?

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Equities researchers at HC Wainwright issued their FY2026 earnings estimates for WAVE Life Sciences in a research report issued to clients and investors on Wednesday, October 28th. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($1.09) per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ Q4 2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.28) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at ($0.47) EPS.

Several other analysts also recently commented on the stock. William Blair started coverage on shares of WAVE Life Sciences in a research report on Friday, October 16th. They set an “outperform” rating for the company. Leerink Partners set a $10.00 target price on shares of WAVE Life Sciences in a research note on Tuesday. Zacks Research cut shares of WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. UBS Group initiated coverage on shares of WAVE Life Sciences in a report on Thursday, October 15th. They issued a “buy” rating and a $11.00 price target for the company. Finally, JPMorgan Chase & Co. started coverage on shares of WAVE Life Sciences in a research note on Wednesday, September 23rd. They issued a “neutral” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.89.

WAVE Life Sciences Stock Performance

Shares of WVE opened at $3.63 on Friday. The firm has a market cap of $715.94 million, a PE ratio of -3.39 and a beta of -1.43. WAVE Life Sciences has a 52-week low of $3.04 and a 52-week high of $21.73. The business’s 50 day moving average price is $4.10 and its two-hundred day moving average price is $7.55.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Tuesday, October 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. The business had revenue of $13.16 million for the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Readystate Asset Management LP purchased a new stake in WAVE Life Sciences during the second quarter valued at about $27,465,000. Squarepoint Ops LLC boosted its stake in WAVE Life Sciences by 68.0% during the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock valued at $14,766,000 after buying an additional 1,029,052 shares during the period. Renaissance Technologies LLC grew its position in WAVE Life Sciences by 152.6% during the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after buying an additional 360,800 shares in the last quarter. Pictet Asset Management Holding SA increased its stake in WAVE Life Sciences by 42.6% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock worth $8,202,000 after acquiring an additional 343,226 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of WAVE Life Sciences in the 1st quarter valued at about $1,138,000. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Insider Activity

In other news, Director Heidi L. Wagner sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the sale, the director directly owned 44,930 shares of the company’s stock, valued at $270,029.30. This trade represents a 13.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Adrian Rawcliffe sold 12,700 shares of WAVE Life Sciences stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 23,564 shares of company stock worth $132,476. 24.34% of the stock is owned by corporate insiders.

Key Headlines Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Third-quarter results beat expectations: WAVE reported $13.16 million in revenue versus the $4.51 million consensus estimate and a loss of $0.30 per share, narrower than the expected $0.33 loss. The results helped reduce near-term concerns about the company’s financial performance. Wave Life Sciences Stock Rallies As Q3 Results Ease Loss Fears
• Positive Sentiment: HC Wainwright initiated coverage with a Strong-Buy rating: The firm’s forecasts call for losses of $1.09 per share in fiscal 2026 and fiscal 2027, narrowing to $0.79 in 2028, $0.68 in 2029 and $0.47 in 2030. The rating indicates confidence in WAVE’s longer-term potential despite continued projected losses. HC Wainwright WAVE Coverage
• Positive Sentiment: Additional bullish attention supported the rally: Reports highlighted WAVE among healthcare stocks viewed favorably by analysts, while separate coverage noted that the shares rose after the strong earnings release. Analysts Are Bullish on WAVE
• Neutral Sentiment: Oppenheimer remained constructive but reduced its price target: The firm lowered its target to $29 from $32 while maintaining an Outperform rating, creating a mixed signal for investors. Oppenheimer Adjusts WAVE Price Target
• Negative Sentiment: Profitability remains a significant risk: HC Wainwright expects WAVE to continue posting quarterly and annual losses through 2030. The company’s negative net margin and ongoing cash needs could limit the durability of the earnings-driven advance.

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.